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p120ctn is a member of the Armadillo protein family. It stabilizes the cadherin–catenin adhesion complex at the plasma membrane, but also
has additional roles in the cytoplasm and nucleus. Extensive alternative mRNA splicing and multiple phosphorylation sites generate additional
complexity. Evidence is emerging that complete loss, downregulation or mislocalization of p120ctn correlates with progression of different types
of human tumors. It remains to be determined whether a causal relationship exists between specific isoform expression, subcellular localization or
selective phosphorylation of p120ctn on the one hand and tumor prognosis on the other.
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Cell–cell interactions, which are mediated by adhesion mole-
cules, play vital roles in developmental morphogenesis, tissue
remodeling and carcinogenesis. One of the major epithelial cell–
cell adhesion molecules, E-cadherin, is frequently lost or down-
regulated in various human cancers. Reduction of its expression
correlateswith the emergence ofmalignant characteristics, such as
loss of epithelial morphology, and gain of invasiveness and
metastatic potential [1,2]. Both reversible and irreversible mecha-
nisms are at play. E-cadherin is somatically inactivated in diffuse-
type gastric cancer and invasive lobular breast cancer [3–5]. On
the other hand, down-regulation of E-cadherin gene expression by
transcriptional silencing (promoter hypermethylation or expres-
sion of specific transcriptional repressors) increases cell motility
and morphological epithelial to mesenchymal transition (EMT)
(reviewed in: [2,6–8]). For instance, the transcriptional repressors
Snail1 and SIP1 are key EMT regulators [8,9] that downregulate
numerous epithelial target genes, including E-cadherin and
many other junctional proteins [10,11].
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MET, at the site of secondary sites [12]. For instance, E-cadherin
expression is dynamically and reversibly modulated during
progression of ductal breast carcinoma [13]. Reduced E-cadherin
expression favors dissemination, but regaining expression favors
survival and reattachment of metastasizing cells [13–15].
Brabletz et al. [14] reported that colorectal carcinomas, which
show E-cadherin downregulation and nuclear β-catenin at the
invasive front, reexpress E-cadherin in their metastases whereas
β-catenin localizes to the PMand the cytoplasm. This is indicative
of aMET process. Recently, the term ‘metastable phenotype’, was
introduced at a recent EMTmeeting in Vancouver [16]. Cells with
this phenotype express both mesenchymal markers (e.g. matrix
metalloproteinases and vimentin) and epithelial markers (kera-
tins) and show some residual E-cadherin expression.
Although it is well known that E-cadherin is an invasion
suppressor in many cancers [2], the molecular basis of this
property is poorly understood. In the past, it had been thought
that E-cadherin acts like molecular glue to inhibit cell move-
ments. The E-cadherin complex contains many cytoplasmic
signaling molecules, including α-catenin and the Armadillo
(Arm) proteins β-catenin, plakoglobin and p120ctn. This
complex has been implicated not only in cell–cell adhesion,
but also in epithelial cell polarity, migration, growth and
survival. Recent studies demonstrated that the E-cadherin–β-
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dynamic rather than a stable link to the cytoskeleton [17,18].
The diverse signals emanating from the E-cadherin complex are
therefore likely to be altered by tumor-associated inactivation of
E-cadherin, resulting in the various cancer phenotypes.
In the last two decades, the adhesive and transcriptional
functions of β-catenin in human malignancies have become
clear [19,20]. Tumor genetics revealed that mutations in
members of the Wnt–β-catenin pathway occur in approxi-
mately 90% of colorectal cancers, as well as in other cancer
types, such as hepatocellular carcinomas [21,22]. Mutations
that activate the Wnt–β-catenin pathway promote stabilization
of β-catenin and induce its nuclear accumulation. This results
in activation of gene transcription, and alteration of cell
migration and polarity. Other mutations, e.g. in conductin or
in the adenomatous polyposis coli (APC) gene product, also
affect the degradation of β-catenin. Activating mutations in
the β-catenin gene itself have been reported in approximately
10% of colorectal cancer and in up to 40% of hepatocellular
carcinomas [23,24]. The role of the Arm protein p120ctn in
malignancies is less clear.
2. Structure of p120ctn isoforms
The human CTNND1 gene comprises 21 exons and encodes
potentially up to 48 protein isoforms due to many inter- and
intra-exonic splicing events [25]. Human isoforms, designated 1
to 4, differ from each other in the start codon used. Alternative
combinations with or without internal exons A–D generate
additional isoforms [25,26]. Typical examples are isoforms
1ABC and 3AB. Several domains have been identified in
p120ctn, including the coiled coil domain found only in isoform
1, and the phosphorylation domain found in all isoforms except
type 4 (see Fig. 1). Isoform 1 (120-kDa or long isoform) and
isoform 3 (100-kDa or short isoform) are expressed predom-
inantly in highly motile fibroblastoid cells and epithelial cells,
respectively [25,27]. The Arm domain of β-catenin consists of a
series of 12 linked repeats of ∼42 amino acids (aa) folded inFig. 1. Schematic diagram of the human p120ctn protein. Multiple isoforms of p120
exons A (exon 18), B (exon 20), C (exon 11) and D (exon 4); sizes are indicated in
leptomycin-B sensitive NES sequences, as indicated. The hinge region containing a N
epitopes are indicated. Armadillo repeats (1 to 9) are depicted by shaded boxes.helical conformation [28]. The proteins p120ctn, δ-catenin,
ARVCF, p0071, and plakophilins (PKP)-1 to -3 belong to a
separate subfamily of Arm proteins. The three-dimensional
structure of the Arm domain of plakophilin-1 reveals nine
instead of the originally predicted ten Arm repeats [29].
3. Expression of p120ctn in various cell compartments and
in tumors
p120ctn associates with most if not all classical (type I) and
nonclassical (type II) cadherins [30]. p120ctn may promote
cell surface trafficking of cadherins through its ability to
complex with kinesin and move vesicles along microtubules
[31–33]. However, other studies indicate that p120ctn does not
bind to the E-cadherin–catenin complex until p120ctn is
located near or at the basolateral membrane [34]. Further,
p120ctn promotes lateral clustering of cadherins [35,36], and
regulates cadherin stability and turnover at the plasma
membrane (PM) [37–39]. It regulates the membrane traffick-
ing route followed by E-cadherin [40]. On arrival at the plasma
membrane (PM), E-cadherin is rapidly degraded in cells that
express low amounts of p120ctn [39]. Treatment of cells with
lysosomal inhibitors prevents cadherin degradation in cells in
which p120ctn expression is knocked down [37,38]. These
studies indicate that p120ctn is required for retaining and
stabilizing E-cadherin molecules at the PM. The precise role of
p120ctn in this process remains unclear. p120ctn also facilitates
the recycling of cadherin back to the cell surface. Calcium switch
experiments have shown that p120ctn accelerates the delivery of
cadherins to the PM via an interaction with kinesin motors
[31,33]. Coupled with the growing literature on p120ctn down-
regulation in tumors of all types, these data indicate that
E-cadherin loss in at least a subset of cancers is due to prior
down-regulation of p120ctn, in addition to other well-described
mechanisms causing E-cadherin deficiency. Nonetheless, direct
evidence is lacking, and very little is known about the timing,
mechanism, or consequences of p120ctn down-regulation
during tumor progression.ctn result from the use of alternative start codons (M) and alternative splicing of
amino acid residues (aa). p120ctn has two consensus NLS sequences and two
LS is also important in regulating Rho function. Approximate locations of mAb
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GTPases present at the adherens junctions or in the cytoplasm
[41–43]. Rho GTPases are critical for diverse cellular functions,
including regulation of actin organization, cell adhesion, cell
polarity, intracellular membrane trafficking, transcription, cell
cycle progression, and cell transformation [44,45]. In addition,
p120ctn interacts with Kaiso [46], which is a transcriptional
repressor belonging to the POZ/BTB family of zinc finger
proteins implicated in development and cancer [47].
The various activities of p120ctn are found in different cell
compartments. Expression of p120ctn has been examined by
immunohistochemistry in a growing number of cancer types. In
this review we will discuss the role of p120ctn in cancer in terms
of its expression and localization patterns in different tumors
(Fig. 2).
Regional loss or down-regulation of p120ctn occurs
frequently in almost all human cancers (Table 1) [48]. This
suggests that p120ctn down-regulation in vivomay be important
in tumor formation or progression. Several studies have indeed
found that p120ctn down-regulation is associated with poor
patient prognosis (Table 1). Moreover, p120ctn is often found in
the cytoplasm of tumor cells, in particularly in poorly
differentiated areas, but only quite rarely in the nucleus [49–51].
4. Role of p120ctn phosphorylation
p120ctn is a most efficient substrate for cellular and onco-
genic Src family tyrosine kinases [52–54]. Among the proteinsFig. 2. p120ctn localization in the cell changes as the cell undergo EMT. Red indic
epithelial cells) shorter p120ctn isoforms bind to E-cadherin present at the adheren
malignant epithelial cells express mainly long p120ctn isoforms. These isoforms occu
(mesenchymal cell 2). Signaling pathways that are repressed by Kaiso may be reliev
GTPases: generally, RhoA is inactivated and Rac1 activated. Mesenchymal cells ma
loss of p120ctn has been reported to activate Rho while Rac-GTP levels remain uncpurified using phosphotyrosine-specific antibodies, p120ctn is a
major phosphorylated substrate [55]. In contrast to most Src
substrates and effectors (e.g. tensin, focal adhesion kinase,
p130CAS, p110AFAP and cortactin), the Arm protein p120ctn
does not harbor the typical domains closely associated with
protein kinase (PTK) signaling (e.g. tyrosine kinase domain,
SH2 or SH3 domains). Also, unlike many Src effectors, which
can regulate the actin cytoskeleton, p120ctn is not widely
considered a direct regulator of actin dynamics. On the other
hand, the functions of p120ctn in cadherin-mediated adhesion
and in Rho-GTPase modulation are consistent with the
collective role of Src substrates.
Cadherins are both necessary and sufficient for localization
of p120ctn to the PM and its phosphorylation by tyrosine
kinases [35]. In cadherin-deficient cells, cytoplasmic p120ctn is
not phosphorylated, while membrane-uncoupled Src mutants
appear to have little access to cadherin-associated p120ctn [52].
Thus phosphorylation of p120ctn by Src requires localization of
both proteins at the PM, the former via cadherin binding, and
the latter by myristoylation of its N-terminal Gly residue.
Shibata et al. [51] showed that tyrosine-phosphorylated p120ctn
accumulates in protrusive domains of the PM.
The role of p120ctn phosphorylation remains poorly defined.
p120ctn can be phosphorylated on numerous Tyr, Ser and Thr
residues, which are mostly present in the regulatory domain
[56]. The phosphorylation status of p120ctn seems to play a
fundamental role in regulating the E-cadherin adhesion complex
[56]. Tyrosine phosphorylated p120ctn destabilizes E-cadherin/ates p120ctn expression. In epithelial cells (or tumors with well differentiated
s junctions. Mesenchymal cells and tumors with poorly differentiated, highly
r either in the cytoplasm (mesenchymal cell 1), or in both cytoplasm and nucleus
ed by the action of nuclear p120ctn. Cytoplasmic p120ctn modulates the Rho-
y also lose p120ctn expression completely (mesenchymal cell 3). Experimental
hanged. See references in the text.
Table 1
p120ctn expression in tumors
Organ No. of cases Absent (%) Altered (%) Clinical correlates Ref.
Bladder 48 6 31% decreased or heterogeneous Correlated with poor prognosis [122]
68 84% decreased Correlated with poor prognosis [123]
102 17 70% decreased or heterogeneous No correlation [124]
Breast (ILC) a 67 0 88% cytoplasmic, 6% nuclear (Ecad-neg) b NA [50]
60 0 92% cytoplasmic NA [51]
Breast (IDC) c 91 10 40% Not correlated with poor prognosis [125]
80 10 58% decreased or heterogeneous Not correlated with poor prognosis [126]
195 2 60% decreased (Ecad-neg), 10% cytoplasmic NA [50]
60 92% cytoplasmic (Ecad-neg) NA [51]
Colorectal 13 23 46% cytoplasmic NA [127]
20 100% decreased or heterogeneous NA [128]
44 18 68% decreased or heterogeneous Correlated with poor prognosis [129]
43 21 19% decreased or heterogeneous 25% cytoplasmic Not correlated with tumor stage [130]
557 5.4 53% cytoplasmic (Ecad-neg or cytoplasmic) Correlated with poor survival [96]
Endometrial 149 64% decreased No correlation [131]
Gastric 40 18 15% decreased or heterogeneous, 37% cytoplasmic Not correlated with tumor stage [130]
68 18 15% decreased or heterogeneous, 37% cytoplasmic No correlation [132]
36 56% decreased or heterogeneous No correlation [133]
Gastroesophageal
junction
96 68% decreased Correlated with poor survival [83]
Lung 193 61% decreased or heterogeneous No correlation [134]
143 80% decreased and cytoplasmic Correlated with poor survival [97]
Melanoma 67 Frequently decreased or heterogeneous No correlation [135]
Pancreatic (ductal) 20 15 20% decreased or heterogeneous Not correlated with tumor stage [130]
32 100% increased, cytoplasmic and nuclear Correlated with high grade and poor survival [82]
Prostate 112 49% decreased or heterogeneous Correlated with pathological stage [136]
118 45% decreased or heterogeneous Correlated with pathological stage [137]
88 30% decreased or heterogeneous (Ecad-neg) Correlated with high grade pathological stage [117]
45 22% decreased or heterogeneous NA [49]
Renal 11 No significant change [138]
Skin 29 48 52% decreased or heterogeneous cytoplasmic
and nuclear (Ecad-neg and +)
NA [139]
Synovial sarcoma 15 Expression detected in all samples (Ecad-neg and +) NA [140]
NA: not analyzed in this study.
a ILC: invasive lobular carcinoma.
b IDC: invasive ductal carcinoma.
c Ecad-neg: in E-cadherin-negative cells.
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is no information about the phosphorylation status of p120ctn in
tumor samples. The commercial availability of phospho-
specific antibodies against p120ctn can open opportunities in
this respect [59,60]. One report claimed that N-cadherin
interacts preferentially with the long p120ctn isoforms, and
E-cadherin with the short forms [61]. In the pancreatic tumor
cell system used in this study, long p120ctn isoforms asso-
ciated with N-cadherin were found to be phosphorylated at
Tyr residues, whereas the short p120ctn isoforms linked to
E-cadherin were not.
Beta-catenin phosphorylation has a central role in adherens
junctions. Cadherin-mediated adhesions are maintained by
ensuring that β-catenin remains dephosphorylated, which
requires the presence of tyrosine phosphatase activity [62].
When tyrosine kinase activity is elevated, β-catenin is
phosphorylated, cadherin-mediated adhesion is compromised,
and metastatic potential may increase [63]. It was shown that
phosphorylation of β-catenin is regulated by the combined
activities of the tyrosine kinase Fer and the tyrosine phosphatase
PTP1B [64]. p120ctn is also important in this dephosphoryla-tion process, as Fer interacts with cadherin indirectly through
p120ctn [64–66]. One function of Fer is to phosphorylate
PTP1B, which facilitates the binding of PTP1B to the cadherin
cytoplasmic domain and stabilizes adhesion through dephos-
phorylation of β-catenin.
Epidermal growth factor (EGF) has been shown to induce
tyrosine phosphorylation of β-catenin and plakoglobin after
association with the cadherin–catenin complex. It has been
argued that this induces disassembly of the cadherin–catenin
complex from the actin filament network [67]. EGFR is
frequently overexpressed in many malignancies, and its over-
expression in primary human esophageal keratinocytes leads to
enhanced cell migration. But at the same time it induces a shift
in the distribution of p120ctn from the cytoplasm to the
membrane, thereby resulting in increased cell adhesion [68].
This example illustrates bi-directional regulation of receptor
tyrosine kinases versus E-cadherin similar to that shown by
Qian et al. [69], who reported that E-cadherin mediated
adhesion inhibits receptor tyrosine kinase activity. E-cadherin
was found to interact through its extracellular domain with
EGFR and other receptor kinases, thereby decreasing receptor
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receptor kinases, which indicates that downregulation of
E-cadherin may contribute to the frequently observed activation
of receptor kinases in tumors.
5. Role of p120ctn in the cytoplasm
Down-regulation of E-cadherin in cancer can result in
redistribution of p120ctn to the cytoplasm. Loss of p120ctn or
its localization to the cytoplasm seems to alter tissue
homeostasis and promote metastasis independently of its role
in adhesion. An example to this is that down-regulation of
endogenous p120ctn in E-cadherin-deficient breast cancer cells
prevented migratory phenotypes [51]. The activity of Rho
GTPases is finely tuned by GTP binding and GTP hydrolysis.
Apparently, p120ctn in the cytoplasm can both down-regulate
[41–43] and up-regulate active RhoA [70], and/or activate
Rac1. It has also been reported that p120ctn regulates Rho
activity in a cell-context dependent manner [70]. Rho-GTPases
regulate many cellular processes, including actin organization,
cell migration and cell polarity [71,72]. Several lines of
evidence implicate Rho family members in a variety of
important processes in cancer, including cell transformation,
survival, proliferation, invasion, metastasis, and angiogenesis
[73]. p120ctn regulates Rho GTPases in vivo, as ablation of
p120ctn in the epidermis and its appendages was associated
with a marked increase in active RhoA even though total RhoA
levels remained unchanged [74]. No obvious differences were
detected in the Rac1 and Cdc42 GTP pulldown assays on these
tissues. Similarly, knockdown of cytoplasmic p120ctn by RNA
interference in a human breast cancer cell line did increase
levels of active Rho-GTP, whereas levels of Rac-GTP remained
unchanged [51]. Until now no direct link between cytoplasmic
p120ctn and alteration in Rho-GTPases levels in tumors has
been reported.
An association of p120ctn with microtubules has been
reported recently [32,75]. Mutation of particular Ser residues
within the Arm repeat domain of p120ctn to Ala (mutant AAA-
p120ctn) promotes association of p120ctn with interphase
microtubules [32]. Localization to the microtubules also
depends on a Lys-rich motif in the Arm domain. In addition,
AAA-p120ctn localizes to the mitotic spindle and centrosomes.
In the breast cancer cell line MDA-MB-231 a fraction of
endogenous p120ctn was detected at the centrosomes or the
pericentrosomal region. The mutant AAA-p120ctn did not
activate Rac and did not induce the dendritic morphology,
typical of Rho inactivation upon WT p120ctn overexpression.
As the binding of p120ctn to the microtubules and its ability to
activate Rac are mutually exclusive, an inverse relationship
between the two activities was proposed [32].
6. Role of p120ctn in the nucleus
In addition to its roles in cadherin-mediated adhesion and
regulation of Rho family GTPases, p120ctn has also been found
in the nucleus. In E-cadherin deficient cell lines, p120ctn is
frequently observed both in the cytoplasm and in the nucleus[50,51,75–77]. Two putative p120ctn nuclear localization
signals (NLS) were described: one in the phosphorylation
domain and one in the Arm domain. The NLS in the Arm
domain has been shown to target a heterologous protein to the
nucleus [78] and to influence the subcellular localization of
p120ctn isoform 1, although an alternate import pathway was
not excluded. Deleting these NLSs [75] or mutating two
positively charged Lys residues in one or both putative NLSs
(our observations) does not prevent nuclear translocation of
p120ctn isoform 3 in a convincing manner. This suggests that
particular p120ctn isoforms utilize different pathways for
nucleocytoplasmic trafficking. At least for isoform 3A, the
nuclear import of p120ctn is dependent on the Arm domain
[75]. This finding is consistent with data on other Arm domain
proteins. For instance, nuclear import of β-catenin has been
proposed to be mediated by its direct interaction with
nucleoporins [79,80], although a subsequent study has
challenged this view [81]. On the other hand, nuclear export
signals (NES) are present in p120ctn isoforms encoding exon B
(exon 20) [76] and in Arm repeat 7 (formerly named Arm repeat
8) [75].
Nuclear immunoreactivity of p120ctn has been observed in
different adenocarcinomas [50,75,82,83]. Nuclear localization
of p120ctn is associated mostly with its cytoplasmic localiza-
tion. Mayerle et al. [82] could not firmly distinguish by
immunohistochemistry between cytosolic and nuclear localiza-
tion of p120ctn in human pancreatic cancers, so they performed
immuno-electron microscopy studies. They confirmed abun-
dant cytosolic localization and also nuclear import of p120ctn in
tumor cells, particularly in high-grade undifferentiated tumors.
We also stained series of different types of tumors, but nuclear
p120ctn was never as prominent as nuclear β-catenin (our
unpublished data). Checking various photographs of p120ctn
staining in published articles revealed similar results.
Kaiso is a ubiquitously expressed transcription factor with
a BTB/POZ structure (broad complex, Tramtrack, Bric a
brac/pox virus and zinc finger). It was originally identified in
a yeast two-hybrid screen for binding partners of p120ctn
[46]. Kaiso demonstrates bi-modal DNA-binding activity: it
binds methylated CpG dinucleotides or a sequence-specific
consensus Kaiso binding site [84,85]. Several cancer-related
gene fragments, such as regulatory sequences of the genes Rb,
Xist, S100A4 (mts-1), CDH1 (E-cadherin), matrilysin (MMP7),
MTA2 (metastasis-associated gene 2) and Wnt11, have been
proposed as possible sites to which Kaiso binds to repress
transcription [84–87].Most interesting is the report by Park et al.
[88] that Kaiso works in conjunction with T-cell factor (TCF) in
repressing known canonical Wnt target genes, at least in Xeno-
pus laevis. In this system, p120ctn was clearly shown to relieve
Kaiso-mediated transcriptional repression. On the other hand,
the rapsyn core promoter was recently shown to be up-regulated
by a complex of Kaiso with δ-catenin in subsynaptic nuclei of
neuromuscular junctions [89]. Although we detected p120ctn
and Kaiso separately in the nucleus, we were unable to detect
their colocalization there [49]. In contrast, the presence of both
proteins in the cytoplasm was evident in various tumors. It is
conceivable that Kaiso is retained in the cytoplasm or excluded
83J. van Hengel, F. van Roy / Biochimica et Biophysica Acta 1773 (2007) 78–88from the nucleus by its interaction with cytoplasmic p120ctn. It
has been shown that nuclear p120ctn relieves Kaiso-mediated
transcriptional repression in cultured cells, but NLS-defective
p120ctn does not [78]. The common cytoplasmic location of
p120ctn and Kaiso in vivo could mean that p120ctn inhibits
Kaiso transcriptional repression by dissociating it from the
DNA, followed by nuclear export of the p120ctn/Kaiso complex
and its sequestration in the cytoplasm, rather than by directly
blocking its binding to DNA in the nucleus [47]. Kaiso
relocalization may contribute to tumor progression, but this
needs to be investigated extensively.
The phenotype of Kaiso-deficient mice provides some
support for Kaiso's putative role in tumorigenesis. Kaiso-null
mice were viable, fertile, and had no detectable abnormalities in
development or gene expression [90]. However, these mice are
somewhat more resistant to intestinal tumorigenesis when bred
onto an APCMin/+genetic background. Min mice are heterozy-
gous for a mutation that truncates Apc (the adenomatous
polyposis coli gene) and are a model for human familial
adenomatous polyposis. The Apc mutation results in the
stabilization of β-catenin, thereby promoting activation of the
canonical Wnt pathway. This observation is in line with models
of cancer progression in which methyl-CpG-associating
transcriptional repressors such as MBD2 or Kaiso (or Kaiso-
like proteins) reduce the expression of gene products that would
normally counter tumor formation. Surprisingly, no difference
in expression of four reported Kaiso target genes (S100A4,
Mta2, Rapsyn, and Wnt11) were found in the Kaiso-null mice.
This indicates that there is some redundancy in the control of
these genes, and that other Kaiso target genes may be involved
in the tumor phenotype. It is also not clear whether association
of p120ctn with Kaiso plays a role in promoting tumors caused
by Apc mutations.
7. Isoform switches for p120ctn and cadherins in cancer
It was observed that the 100-kDa (short) and 120-kDa (long)
isoforms (see Fig 1) are expressed predominantly in, respec-
tively, epithelial cells and highly motile fibroblastoid cells
[25,27]. Monoclonal antibodies 2B12, 5A7 and 6H11 recognize
the longer isoforms specifically [91]. A shift from short to long
p120ctn isoform expression was seen in FosER cells, in which
EMT is induced as a consequence of the activation of a cFos-
estrogen receptor fusion protein by the addition of estradiol
[92]. A similar reduction in the amount of the 100-kDa forms
and an increase in the longer isoforms was seen in anaplastic
thyroid carcinoma cell lines [93], and in prostate carcinoma cell
lines [94].
Various EMT-inducing transcriptional repressors (Snail,
E47, Slug, SIP1/ZEB2) can induce p120ctn isoform switches.
In MDCK epithelial cells, Snail-induced EMT causes striking
transition from the “epithelial” to the “mesenchymal” p120ctn
isoform pattern [95], consistent with a motility/invasion role for
the longer isoform 1. The p120ctn isoform switch is not
reversed by re-expression of E-cadherin, indicating that the
effect is Snail-induced and not directly caused by E-cadherin
down-regulation. It also means that the expression of p120ctnisoforms is regulated at the level of transcript maturation rather
than stability.
Likewise, Sarrio et al. [50] reported that expression of Snail,
E47 or Slug in MDCK cells provokes p120ctn cytoplasmic
localization and isoform switching. Longer and shorter p120ctn
isoforms were also inversely regulated during a SIP1/ZEB2-
induced EMT-like process in human epithelial cancer cell lines
[10]. Up-regulation of p120ctn isoform 1 and down-regulation
of isoform 3 during EMT indicate that different isoforms may
have specific roles in epithelial versus mesenchymal states.
Nonetheless, a p120ctn isoform switch is not always seen
during EMT. For example, no isoform switch was observed in a
recent study of EMT in highly differentiated colon carcinoma
cells treated with TGF-β and TNF-α [96]. Recently, Wang et al.
[97] reported abnormal expression of p120ctn in lung squamous
cell carcinoma and adenocarcinoma. Expression of long and
short isoforms in normal lung and tumor lung tissue was
detected by Western blot analysis. Both long and short isoforms
were reduced in tumor tissues. Most other analyses of p120ctn
isoforms published to date deal with tumor cell lines rather than
original tumor specimens, although immunohistochemical
analysis of the latter using isoform-specific antibodies could
be most instructive.
The shorter p120ctn isoforms have been reported to
preferentially interact with E-cadherin in the pancreatic tumor
cell line MIA PaCa-2, whereas the longer isoform 1 interacts
with N-cadherin [61]. However, working in several tumor cell
systems, other researchers could not reproduce this isoform
preference for particular cadherin types [98,99] (K. Johnson,
personal communication). In several cancer types, including
melanoma, prostate and breast cancer, loss of E-cadherin
function is accompanied by de novo expression of mesenchy-
mal cadherins, such as N-cadherin and cadherin-11 [100,101].
N-cadherin has been shown to promote cell motility and
migration, which is opposite to the effect of E-cadherin
[102,103]. Different types of cadherins may regulate cell
movements by controlling the levels of p120ctn present in the
cytoplasmic pool. E-cadherin appears to bind p120ctn more
tightly than N-cadherin [104]. Coimmunoprecipitation experi-
ments showed that p120ctn binds somewhat more efficiently to
VE-cadherin than to N-cadherin [105]. On the other hand,
P-cadherin appears to have a lower affinity than N-cadherin for
p120ctn [106]. However, affinity studies on p120ctn binding
using surface plasmon resonance measurements have not been
published. Overexpression of P-cadherin is strongly associated
with cytoplasmic accumulation of p120ctn and activation of the
Rho-GTPases Rac1 and Cdc42 [106]. This implies that a
cadherin switch, which may also induce a p120ctn isoform
switch, may be involved in tumor progression.
In the p120ctn-deficient cell line SW48, reconstitution of
cell–cell adhesion by p120ctn isoform 4 causes significantly
better rescue of epithelial morphology than p120ctn isoforms 1
and 3, indicating that the amino-terminal sequence has some
negative effect on cell–cell adhesion [39]. This phenomenon
was also seen in Colo205 cells, which express all members of
the cadherin complex. Their epithelial morphology is efficiently
rescued by an amino-terminally truncated mutant (similar to
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p120ctn-mediated stabilization of cadherins may not be
sufficient by itself to achieve strong cell–cell adhesion. As
the longer isoforms can readily stabilize cadherins, signaling,
presumably through the N-terminal end of p120ctn, can
apparently block cell–cell adhesion despite this stabilization.
Finally, p120ctn isoform switches could explain why Kaiso
was coprecipitated efficiently by p120ctn from several epithelial
cell lines but inefficiently by p120ctn from fibroblasts [46].
8. Are other p120ctn family members involved in cancer?
In mammals, p120ctn has three close family members
(ARVCF, delta-catenin and p0071), which have at least partly
redundant functions. Indeed, each of them can interact with
classic cadherins through its Arm domain, and ARVCF and δ-
catenin can rescue cadherin stability in vitro in p120ctn-
deficient cell lines [37,108]. These proteins share >45% amino
acid sequence identity in their Arm-repeat domains. Another
group in the p120ctn family shares ∼30% identity with the
p120ctn Arm-repeat domain and does not interact with classical
cadherins. In this second group, PKP 1, 2 and 3 localize to
desmosomes, as well as to the cytoplasm and nucleus [109].
PKP3 is reportedly elevated in non-small cell lung
carcinomas [110]. Another study analyzed the subcellular
localization of the three PKPs and p0071 in oropharyngeal
squamous cell carcinomas [111]. PKP1 and PKP3 immunore-
activity was inversely correlated with tumor histological grade,
and it was observed only in oropharyngeal tumors that did not
metastasize. In contrast, strong PKP2 immunoreactivity was
observed in most metastatic tumors. The data indicate that
cytoplasmic versus membranous localization of the individual
PKPs has prognostic value. Because the nuclear functions of
these proteins have not yet been identified, the significance of
immunoreactivity of the different proteins in the cytoplasm and/
or nucleus requires further investigation.
Delta-catenin was initially identified as a presenilin-binding
protein [112,113] and as a neuronal adhesive junction-
associated protein that is expressed primarily in the brain
[114]. Other studies showed weak expression of δ-catenin in
other organs, such as the pancreas and retina [112,115]. Delta-
catenin expression might be closely associated with cancer, as
indicated by enhanced δ-catenin transcription in prostate cancer
compared with benign prostate hyperplasia [116]. In a recent
study of primary prostate adenocarcinomas, examination of the
same tumor cell clusters using consecutive sections showed that
increased δ-catenin immunoreactivity was accompanied by
down-regulation and redistribution of E-cadherin and p120ctn,
especially in tumors with poor prognosis [117]. It is important to
determine whether δ-catenin expression precedes or follows
p120ctn and E-cadherin down-regulation, and whether the same
inverse correlation holds for other tumor types. In addition, it is
not junctional δ-catenin that compensates for loss of junctional
E-cadherin and p120ctn, because all three proteins, including
δ-catenin, localize in the cytoplasm when δ-catenin levels are
increased [117]. On the other hand, in a search for candidate
tumor suppressor genes, a recent siRNA-based screen onsemitransformed human mammary epithelial cells yielded
δ-catenin as one of the eight strongest candidates able to
suppress anchorage-independent growth [118].
9. p120ctn knockout studies in mouse
To examine the in vivo consequence of p120ctn ablation,
Davis and Reynolds [119] conditionally ablated p120ctn in
mice, either in the embryonic salivary gland or in the epithelia
of the small intestine and colon. Moreover, in collaboration with
E. Fuchs and colleagues, they ablated p120ctn in the epidermis
[74]. Morphological and adhesive defects were present in most
of the p120ctn-null tissues, and E-cadherin expression was
strongly reduced but not completely blocked. It is important to
check whether other p120ctn family members can compensate
for this ablation and stabilize E-cadherin expression to some
extent. Total p120ctn knockout in mice is embryonically lethal
at early stage [119].
p120ctn ablation in the submandibular gland induced
dysplasia, cell shedding and epithelial masses that retained the
ability to proliferate and escape apoptosis [119]. These
manifestations, in combination with defects in epithelial
morphology and adhesion, are indistinguishable from high-
grade intraepithelial neoplasia, a precancerous condition that in
man usually progresses to invasive cancer. Mice lacking
p120ctn in the epidermis show hyperproliferation of the
epidermis as well as an inflammatory response due to activation
of NFκB [74]. This response could be relevant to understanding
why loss or reduced activity of p120ctn has been correlated with
inflammatory bowel disease, particularly active ulcerative
colitis and active Crohn's disease [120], which are known to
predispose intestinal tissue to cancer [121]. More p120ctn
knockout studies in combination with mouse tumor models
might reveal much about the complex role of p120ctn in cancer.
10. Conclusions and future directions
Many advances have been made in understanding the roles
of p120ctn in cancer. Animal models seem to confirm the
causative roles of p120ctn in different diseases, including
cancer, as had been indicated by earlier studies on cancer cell
lines. However, many important unanswered questions remain.
What are the consequences of alternative splicing of p120ctn
and how is it regulated? How is the promoter (or promoters) of
the various p120ctn transcripts regulated? Do p120ctn muta-
tions or LOH occur in tumors? Why have no cell lines lacking
p120ctn expression been identified so far? Does cytoplasmic or
nuclear p120ctn play a decisive role in tumorigenesis or tumor
progression?
It is necessary to correlate the expression and localization
patterns of p120ctn with E-cadherin expression patterns, tumor
stage, metastatic property and patient survival. A significant start
has been made in this direction [50,51,96], but more studies are
needed, and it will also become important to use isoform-
specific antibodies for p120ctn on human tumor samples.
Comprehensive analysis of expression levels and localization of
representative cadherins, Armadillo proteins, and both
85J. van Hengel, F. van Roy / Biochimica et Biophysica Acta 1773 (2007) 78–88regulator and effector gene products of cadherins and catenins
might reveal the relevant signaling pathways in particular
tumor types, and open opportunities for the development of
effective targeted therapies.
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